共 131 条
- [1] Arias CA(2010)Management of multidrug-resistant enterococcal infections Clin Microbiol Infect 16 555-562
- [2] Contreras GA(2009)Therapeutic options for infections due to vancomycin-resistant enterococci Expert Opin Pharmacother 10 785-796
- [3] Murray BE(2014)Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia Antimicrob Agents Chemother 58 734-739
- [4] Wang JL(2014)Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis BMC Infect Dis 14 687-878
- [5] Hsueh PR(2016)Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose Clin Microbiol Infect. 22 890-1117
- [6] Balli EP(2015)Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients Clin Infect Dis 61 871-613
- [7] Venetis CA(2006)Bactericidal agents in the treatment of MRSA infections—the potential role of daptomycin J Antimicrob Chemother 58 1107-1034
- [8] Miyakis S(2017)Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients Clin Infect Dis 64 605-1657
- [9] Chuang YC(2017)Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible enterococcus faecium bacteremia Clin Infect Dis 64 1026-1520
- [10] Wang JT(2019)pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint Clin Infect Dis 68 1650-992